secwatch.observer — SEC 8-K summary
======================================

Issuer:     NORTHWEST BIOTHERAPEUTICS INC (NWBO)
CIK:        0001072379
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001104659-26-040260
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Northwest Biotherapeutics completes acquisition of UK CDMO Advent BioServices for ~$1.9M plus ~$8.3M payables
--------------------------------------------------------------------------------

- Total consideration: ~$1.9M (£1.4M) purchase price plus ~$8.3M in accounts payable to Advent; unpaid balance accrues 7.5% interest.
- Payment in installments over 2 years starting 3 months after close, with potential acceleration upon DCVax-L regulatory approval.
- Related-party transaction: CEO Linda Powers controls seller; approved per company policies.
- Company retired 12M shares and cancelled 5.5M stock options previously issued to Advent.
- SEC granted waiver from providing Advent financial statements and pro forma info under Regulation S-X.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1072379/000110465926040260/0001104659-26-040260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1072379/000110465926040260/tm2611284d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-040260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer